Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TECX
HOLDTectonic Therapeutic, Inc. · Healthcare · United States · $573M · Avg Vol: $6M/d
COMPANY DESCRIPTION
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing G protein-coupled receptor (GPCR)-targeted therapeutics. Leveraging its proprietary GEODe platform, Tectonic aims to create precise and potent modulators for challenging GPCR targets implicated in various diseases. The company operates as a niche, preclinical-stage platform biotech, distinguishing itself through its advanced structural biology and computational approaches to drug discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -2.18 | -2.91 | -6.83 | -4.05 | — | -4.39 | -5.32 | -5.68 | — |
| Shares | 14.7M | 14.7M | 14.9M | 18.7M | +27.2% | 18.9M | — | — | — |
| Debt | 5.8M | 4.3M | 3.3M | 1.3M | -39.6% | 4.6M | — | — | — |
| Equity | -45.7M | -84.6M | 140.8M | 251.3M | 78.5% | — | — | — | — |
| Op CF | -27.6M | -40.7M | -59.1M | -60.1M | — | -65.4M | — | — | — |
| Inv CF | -2.1M | -0.3M | -0.2M | -0.1M | — | — | — | — | — |
| Fin CF | 37.6M | 33.7M | 171.7M | 173.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TECX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TECX | Tectonic Therapeutic, Inc.(you) | $573M | 36 | HOLD |
| CTNM | Contineum Therapeutics, Inc. | $526M | 37 | HOLD |
| GYRE | Gyre Therapeutics, Inc. | $662M | 36 | HOLD |
| IMMX | Immix Biopharma, Inc. | $607M | 31 | SELL |
| NGNE | Neurogene Inc. | $696M | 33 | SELL |
| CADL | Candel Therapeutics, Inc. | $700M | 33 | SELL |
| OVID | Ovid Therapeutics Inc. | $435M | 33 | SELL |
| CLYM | Climb Bio, Inc. | $735M | 40 | HOLD |
| 0KCS.L | OPKO Health, Inc. | $734M | 31 | SELL |
| FDMT | 4D Molecular Therapeutics, Inc. | $526M | 27 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%